Carmustine Obvius



This medicine is authorised for use in the European Union.


Carmustine Obvius is a cancer medicine that is used, on its own or with other cancer medicines and treatments, to treat the following types of cancer:

  • brain tumours, both those that develop directly in the brain and cancers that have spread from elsewhere in the body (metastatic brain tumours);
  • Hodgkin’s lymphoma and non-Hodgkin’s lymphomas, types of cancer that originate from white blood cells. The medicine is used when initial treatment has not worked or the cancer has come back.
  • Carmustine Obvius is also used as a ‘conditioning’ treatment before transplantation of the patient’s own haematopoietic progenitor cells (immature cells that are able to produce the cells of the blood) to treat Hodgkin’s lymphoma and non-Hodgkin’s lymphomas. It is used to clear the patient’s bone marrow and make room for the transplanted cells.

Carmustine Obvius is a ‘generic medicine’. This means that Carmustine Obvius contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Carmubris.

This EPAR was last updated on 21/10/2020

Authorisation details

Product details
Carmustine Obvius
Agency product number
Active substance
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
  • Hodgkin Disease
  • Lymphoma, Non-Hodgkin
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Obvius Investment B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
De Cuserstraat 93
1081 CN Amsterdam

Product information

02/09/2020 Carmustine Obvius - EMEA/H/C/004326 - N/0004


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Carmustine is effective in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):

  • Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases
  • Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease
  • as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma).

Assessment history

How useful was this page?

Add your rating
1 rating
4 ratings